Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery

Completed · Phase 2

Conditions studied: Pseudophakic Cystoid Macular Edema,, Diabetic Macular Edema

In brief

The purpose of the study is to determine where a sustained steroid delivery system (Ozurdex,Allergan) is safe and effective to treat Cystoid Macular Edema in diabetic patients after Cataract Surgery

Key facts

Study ID

NCT01284478

Run by

Northern California Retina Vitreous Associates

People needed

6

Starts

2011-01-01

Expected to finish

2012-10-01

Last updated by the study team

2012-10-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• DIABETIC PATIENTS WHO DEVELOP CYSTOID MACULA EDEMA AFTER CATARACT SURGERY (WITHIN 4-10 WEEKS AFTER SURGERY
• VISUAL ACUITY WORSE THAN 20/32

You may not qualify if…

• VISUAL ACUITY WORSE THAN 20/200
• MODERATE OR SEVERE GLAUCOMA (AS DEFINED AS USING >2 TOPICAL GLAUCOMA MEDIATIONS.
• USE OF SYSTEMIC, PERIOCULAR OR INTRAOCULAR CORTICOSTEROIDS WITHIN 30 DAYS OF ENROLLMENT

Where it is running

• Northern California Retina Vitreous Associates — Mountain View, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.